Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?

References

• Terui-KohbataH, YoshidaM. Current condition of genetic medicine for hereditary breast cancer. Mol Clin Oncol. 2017;7:98–102. doi:10.3892/mco.2017.126028685084
   PubMed Web of Science ®Google Scholar
• EastonDF, PharoahPDP, AntoniouAC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–2257. doi:10.1056/NEJMsr150134126014596
   PubMed Web of Science ®Google Scholar
• BergomC, WestCM, HigginsonDS, et al. The implications of genetic testing on radiation therapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys. 2019;105:698–712. doi:10.1016/j.ijrobp.2019.07.02631381960
   PubMed Web of Science ®Google Scholar
• TungNM, BougheyJC, PierceLJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38:2080–2106. doi:10.1200/JCO.20.0029932243226
   PubMed Web of Science ®Google Scholar
• ShiovitzS, KordeLA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1219–1291. doi:10.1093/annonc/mdv022
   Web of Science ®Google Scholar
• FordD, EastonDF, PetoJ. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995;57:1457–1462.8533776
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature1141223000897
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAM, TimmsKM, LiuS, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–1089. doi:10.1158/1078-0432.ccr-10-256021233401
   PubMed Web of Science ®Google Scholar
• MavaddatN, BarrowdaleD, AndrulisIL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–147. doi:10.1158/1055-9965.epi-11-077522144499
   PubMed Web of Science ®Google Scholar
• RischHA, McLaughlinJR, ColeDE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694–1706. doi:10.1093/jnci/djj46517148771
   PubMed Web of Science ®Google Scholar
• RakhaEA, Reis-FilhoJS, EllisIO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–2581. doi:10.1200/JCO.2007.13.174818487574
   PubMed Web of Science ®Google Scholar
• LeeEH, ParkSK, ParkB, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and metaanalysis. Breast Cancer Res Treat. 2010;122:11–25. doi:10.1007/s10549-010-0859-220376556
   PubMed Web of Science ®Google Scholar
• BarettaZ, MocellinS, GoldinE, et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine. 2016;95:e4975. doi:10.1097/MD.000000000000497527749552
   PubMed Web of Science ®Google Scholar
• CopsonER, MaishmanTC, TapperWJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–180. doi:10.1016/S1470-2045(17)30891-429337092
   PubMed Web of Science ®Google Scholar
• PetitjeanA, AchatzMI, Borresen-DaleAL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–2165. doi:10.1038/sj.onc.121030217401424
   PubMed Web of Science ®Google Scholar
• LiFP, FraumeniJF, MulvihillJJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362.3409256
   PubMed Web of Science ®Google Scholar
• MaiPL, BestAF, PetersJA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute LiFraumeni syndrome Cohort. Cancer. 2016;122:3673–3681. doi:10.1002/cncr.3024827496084
   PubMed Web of Science ®Google Scholar
• KamiharaJ, RanaHQ, GarberJE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014;35:654–662. doi:10.1002/humu.2255924706533
   PubMed Web of Science ®Google Scholar
• McCuaigJM, ArmelSR, NovokmetA, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time?Fam Cancer. 2012;11:607–613. PMID: 22851211. doi:10.1007/s10689-012-9557-z22851211
   PubMed Web of Science ®Google Scholar
• GonzalezKD, BuzinCH, NoltnerKA, et al. High frequency of de novo mutations in Li–Fraumeni syndrome. J Med Genet. 2009;46:689–693. doi:10.1136/jmg.2008.05895819556618
   PubMed Web of Science ®Google Scholar
• Melhem-BertrandtA, BojadzievaJ, ReadyKJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118(4):908–913. doi:10.1002/cncr.2637721761402
   PubMed Web of Science ®Google Scholar
• RathMG, MasciariS, GelmanR, et al. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013;139:193–198. doi:10.1007/s10549-012-2375-z23580068
   PubMed Web of Science ®Google Scholar
• PackwoodK, MartlandG, SommerladM, et al. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). J Pathol Clin Res. 2019;5(3):189–198. doi:10.1002/cjp2.13331041842
   PubMedGoogle Scholar
• LiaoH, LiH. Advances in the detection technologies and clinical applications of circulating tumor DNA in metastatic breast cancer. Cancer Manag Res. 2020;12:3547–3560. doi:10.2147/CMAR.S24904132547192
   PubMed Web of Science ®Google Scholar
• OvergaardJ. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000;39(3):327–333. doi:10.1080/02841860075001309610987229
   PubMed Web of Science ®Google Scholar
• BartekJ, BartkovaJ, LukasJ. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26(56):7773–7779. doi:10.1038/sj.onc.121088118066090
   PubMed Web of Science ®Google Scholar
• Geoffroy-PerezB, JaninN, OssianK, et al. Cancer risk in heterozygotes for ataxia–telangiectasia. Int J Cancer. 2001;93:288–293. doi:10.101002/ijc.132911410879
   PubMed Web of Science ®Google Scholar
• BremerM, KlöpperK, YaminiP, et al. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol. 2003;69:155–160. doi:10.1016/j.radonc.2003.08.00414643952
   PubMed Web of Science ®Google Scholar
• ThompsonD, DuedalS, KirnerJ, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97:813–822. doi:10.1093/jnci/dji14115928302
   PubMed Web of Science ®Google Scholar
• RenwickA, ThompsonD, SealS, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38:873–875. doi:10.1038/ng183716832357
   PubMed Web of Science ®Google Scholar
• LavinMF, ScottS, GuevenN, et al. Functional consequences of sequence alterations in the ATM gene. DNA Repair. 2004;3(8–9):1197–1205. doi:10.1016/j.dnarep.2004.03.01115279808
   PubMed Web of Science ®Google Scholar
• ScottSP, BendixR, ChenP, et al. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA. 2002;99:925–930. doi:10.1073/pnas.01232969911805335
   PubMed Web of Science ®Google Scholar
• MullinsBT, GuptaG. Increased radiation toxicity with germline ATM variant of uncertain clinical significance. Rep Pract Oncol Radiother. 2019;24:672–680. doi:10.1016/j.rpor.2019.09.00831719806
   PubMedGoogle Scholar
• VenkitaramanAR. How do mutations affecting the breast cancer genes BRCA1 and BRCA 2 cause cancer susceptibility?DNA Repair. 2019;81:102668. doi:10.1016/j.dnarep.2019.10266831337537
   PubMed Web of Science ®Google Scholar
• MoynahanME, PierceAJ, JasinM. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7:263–272. doi:10.1016/S10972765(01)00174-511239455
   PubMed Web of Science ®Google Scholar
• CareyLA. Targeted chemotherapy? Platinum in BRCA1 – dysfunctional breast cancer. J Clin Oncol. 2010;28:361–365. doi:10.1200/JCO.2009.24.083820008634
   PubMed Web of Science ®Google Scholar
• KanC, ZhangJ. BRCA1 mutation: a predictive marker for radiation therapy?Int J Radiat Oncol Biol Phys. 2015;93:281–293. doi:10.1016/j.ijrobp.2015.05.03726383678
   PubMed Web of Science ®Google Scholar
• BarwellJ, PangonL, GeorgiouA, et al. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. 2007;121:1631–1636. doi:10.1002/ijc.2291517582599
   PubMed Web of Science ®Google Scholar
• ShenSX, WeaverZ, XuX, et al. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene. 1998;17:3115–3124. doi:10.1038/sj.onc.12022439872327
   PubMed Web of Science ®Google Scholar
• ForayN, RandrianarisonV, MarotD, et al. Gamma-rays induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene. 1999;18:7334–7342. doi:10.1038/sj.onc.120316510602489
   PubMed Web of Science ®Google Scholar
• BaertA, DepuydtJ, Van MaerkenT, et al. Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation. Breast Cancer Res. 2016;18:52–64. doi:10.1186/s13058-016-0709-127184744
   PubMed Web of Science ®Google Scholar
• BaertA, DepuydtJ, Van MaerkenT, et al. Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncol Rep. 2017;37:1379–1386. doi:10.3892/or.2017.540728184943
   PubMed Web of Science ®Google Scholar
• RobsonME, ChappuisPO, SatagopanJ, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:8–17. doi:10.1186/bcr658
   PubMed Web of Science ®Google Scholar
• PierceLJ, LevinAM, RebbeckTR, et al. Ten-year multi-institutional results of breastconserving surgery and radiotherapy in BRCA1/2 associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–2443. doi:10.1200/JCO.2005.02.788816636335
   PubMed Web of Science ®Google Scholar
• BrekelmansCTM, Tilanus-LinthorstMMA, SeynaeveC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867–876. doi:10.1016/j.ejca.2006.12.00917307353
   PubMed Web of Science ®Google Scholar
• KirovaYM, SavignoniA, Sigal-ZafraniB, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010;120:119–126. doi:10.1007/s10549-009-0685-620033769
   PubMed Web of Science ®Google Scholar
• ValachisA, NearchouAD, LindP. Surgical management of breast cancer in BRCA mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144:443–455. doi:10.1007/s10549-014-2890-124567198
   PubMed Web of Science ®Google Scholar
• VallardA, MagnèN, GuyJB, et al. Is breast-conserving therapy adequate in BRCA1/2 mutation carriers? The radiation oncologist’s point of view. Br J Radiol. 2019;92:20170657 1–9. doi:10.1259/bjr.2017065730810334
   PubMed Web of Science ®Google Scholar
• KastanMB, ZhanO, El-DeiryWS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–597. doi:10.1016/0092-8674(92)90593-21423616
   PubMed Web of Science ®Google Scholar
• McllwrathAJ, VaseyPA, RossGM, et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 1994;54:3718–3722.8033090
   PubMed Web of Science ®Google Scholar
• OlivierM, GoldgarDE, SodhaN, et al. Li–Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643–6650.14583457
   PubMed Web of Science ®Google Scholar
• SchonK, TischkowitzM. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167:417–423. doi:10.1007/s10549-017-4531-y29039119
   PubMed Web of Science ®Google Scholar
• McBrideKA, BallingerML, KillickE, et al. Li–Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol. 2014;11:260–271. doi:10.1038/nrclinonc.2014.4124642672
   PubMed Web of Science ®Google Scholar
• KappelS, JanschekE, WolfB, et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family. Breast Cancer Res Treat. 2015;151:671–678. doi:10.1007/s10549-015-3424-125981898
   PubMed Web of Science ®Google Scholar
• BarlowC, BrownKD, DengCX, et al. Atm selectively regulates distinct p53- dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet. 1997;17:453–456. doi:10.1038/ng1297-4539398849
   PubMed Web of Science ®Google Scholar
• WorgulBV, SmilenovL, BrennerDJ, et al. Atm heterozygous mice are more sensitive to radiation induced cataracts than are their wild-type counterparts. Proc Natl Acad Sci. 2002;99:9836–9839. doi:10.1073/pnas.16234969912119422
   PubMed Web of Science ®Google Scholar
• PatersonMC, AndersonAK, SmithBP, et al. Enhanced radiosensitivity of cultured fibroblasts from ataxia telangiectasia heterozygotes manifested by defective colony-forming ability and reduced DNA repair replication after hypoxic gamma-irradiation. Cancer Res. 1979;39:3725–3734.476695
   PubMed Web of Science ®Google Scholar
• ClarkeRA, FangZH, MarrPJ, et al. ATM induction insufficiency in a radiosensitive breast-cancer patient. Aust Radiol. 2002;46:329–335. doi:10.1046/j.1440-1673.2002.01072.x
   Google Scholar
• SuY, SwiftM. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia–telangiectasia mutations. JAMA. 2001;286:2233–2234. doi:10.1001/jama.286.18.2233
   Web of Science ®Google Scholar
• MeyerA, JohnE, DorkT, et al. Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy. Radiother Oncol. 2004;72:319–323. doi:10.1016/j.radonc.2004.07.01015450731
   PubMed Web of Science ®Google Scholar
• JerzakKJ, MancusoT, EisenA. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol. 2018;25(2):176–180. doi:10.3747/co.25.370729719434
   PubMed Web of Science ®Google Scholar
• ShanleyS, McReynoldsK, Ardern-JonesA, et al. LateToxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res. 2006;12:7025–7032. doi:10.1158/1078-0432.CCR-06-124417145824
   PubMed Web of Science ®Google Scholar
• ParkH, ChoiDH, NohJM, et al. Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol. 2014;90:90–94. doi:10.3109/09553002.2013.83550423957571
   PubMed Web of Science ®Google Scholar
• HusznoJ, BudrykM, KołoszaZ, et al. The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation. Contemp Oncol. 2015;19:72–76. doi:10.5114/wo.2015.50014
   Google Scholar
• Fuentes-RaspallMJ, CaragolI, AlonsoC, et al. Apoptosis for prediction of radiotherapy late toxicity: lymphocyte subset sensitivity and potential effect of TP53 Arg72Pro polymorphism. Apoptosis. 2015;20:371–382. doi:10.1007/s10495-014-1056-225398538
   PubMed Web of Science ®Google Scholar
• TanXL, PopandaO, AmbrosoneCB, et al. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;97:255–262. doi:10.1007/s10549-005-9119-216331344
   PubMed Web of Science ®Google Scholar
• SantiR, CeticaV, FranchiA, et al. Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy. Histopathology. 2011;58:455–466. doi:10.1111/j.1365-2559.2011.03770.x21323968
   PubMed Web of Science ®Google Scholar
• WeissbergJB, HuangDD, SwiftM. Radiosensitivity of normal tissues in ataxia– telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys. 1998;42:1133–1136. doi:10.1016/S0360-3016(98)00295-89869240
   PubMed Web of Science ®Google Scholar
• PollardJM, GattiRA. Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol Biol Phys. 2009;74:1323–1331. doi:10.1016/j.ijrobp.2009.02.05719616740
   PubMed Web of Science ®Google Scholar
• FangZ, KozlovS, McKayMJ, et al. Low levels of ATM in breast cancer patients with clinical radiosensitivity. Genome Integr. 2010;1:9–20. doi:10.1186/2041-9414-1-920678261
   PubMedGoogle Scholar
• IannuzziCM, AtencioDP, GreenS, et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002;52:606–613. doi:10.1016/S0360-3016(01)02684-011849780
   PubMed Web of Science ®Google Scholar
• ByrdPJ, SrinivasanV, LastJI, et al. Severe reaction to radiotherapy for breast cancer as the presenting feature of ataxiateleangectasia. Br J Cancer. 2012;106:262–268. doi:10.1038/bjc.2011.53422146522
   PubMed Web of Science ®Google Scholar
• HoAY, FanG, AtencioDP, et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:677–684. doi:10.1016/j.ijrobp.2007.04.01217517479
   PubMed Web of Science ®Google Scholar
• DongL, CuiJ, TangF, et al. Ataxia telangiectasia-mutated gene polymorphisms and acute normal tissue injuries in cancer patients after radiation therapy: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91:1090–1098. doi:10.1016/j.ijrobp.2014.12.04125832699
   PubMed Web of Science ®Google Scholar
• ZhangY, LiuZ, WangM, et al. Single nucleotide polymorphism rs1801516 in Ataxia Telangiectasia-mutated gene predicts late fibrosis in cancer patients after radiotherapy: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2016;95:e3267. doi:10.1097/MD.000000000000326727057881
   PubMed Web of Science ®Google Scholar
• SuM, YinZH, WuW, et al. Meta-analysis of associations between ATM Asp1853Asn and TP53 Arg72Pro polymorphisms and adverse effects of cancer radiotherapy. Asian Pac J Cancer Prev. 2014;15:10675–10681. doi:10.7314/apjcp.2014.15.24.1067525605158
   PubMedGoogle Scholar
• TerrazzinoS, CargninS, DeantonioL, et al. Impact of ATM rs1801516 on late skin reactions of radiotherapy for breast cancer: evidences from a cohort study and a trial sequential meta-analysis. PLoS One. 2019;14:e0225685. doi:10.1371/journal.pone.022568531756226
   PubMed Web of Science ®Google Scholar
• ZhangW, BeccioliniA, BiggeriA, et al. Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy. Breast Cancer Res. 2011;13:38–47. doi:10.1186/bcr2860
   Web of Science ®Google Scholar
• ShethGR, CranmerLD, SmithBD, et al. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17:405–418. doi:10.1634/theoncologist.2011-028222334455
   PubMed Web of Science ®Google Scholar
• NieuwenhuisB, Van Assen-boltAJ, Van Waarde-verhagenMAWH, et al. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol. 2002;78:285–295. doi:10.1080/0955300011009797412020440
   PubMed Web of Science ®Google Scholar
• SpeitG, TrenzK. Chromosomal mutagen sensitivity associated with mutations in BRCA genes. Cytogenet Genome Res. 2004;104(1–4):325–332. doi:10.1159/00007751115162060
   PubMed Web of Science ®Google Scholar
• BayensA, ThierensH, ClaesK, et al. Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. Int J Radiat Oncol Biol. 2004;80(10):745–756. doi:10.1080/09553000400017937
   Web of Science ®Google Scholar
• PijpeA, AndrieuN, EastonDF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENERADRISK). Br Med J. 2012;6:e5660. doi:10.1136/bmj.e5660
   Web of Science ®Google Scholar
• AndrieuN, EastonFD, Chang-ClaudeJ, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol. 2006;24:3361–3366. doi:10.1200/JCO.2005.03.312616801631
   PubMed Web of Science ®Google Scholar
• WarnerE. Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations. Ann Oncol. 2011;22:44–49. doi:10.1093/annonc/mdq665
   Web of Science ®Google Scholar
• SchlosserS, RabinovitchR, ShatzZ, et al. Radiation Associated secondary malignancies in BRCA mutation carriers treated for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107:353–359. doi:10.1016/j.ijrobp.2020.02.02032084523
   PubMed Web of Science ®Google Scholar
• KadouriL, SagiM, GoldbergY, et al. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat. 2013;140:207–211. doi:10.1007/s10549-013-2621-z23824362
   PubMed Web of Science ®Google Scholar
• EvronE, Ben-DavidAM, GoldbergH, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Ann Oncol. 2019;30:412–417. doi:10.1093/annonc/mdy51530475942
   PubMed Web of Science ®Google Scholar
• KasperE, AngotE, ColasseE, et al. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer. 2018;101:254–262. doi:10.1016/j.ejca.2018.06.01130072235
   PubMed Web of Science ®Google Scholar
• SalmonA, AmikamD, SodhaN, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘De-Novo’ TP53 mutation. Clin Oncol. 2007;19:490–493. doi:10.1016/j.clon.2007.05.001
   Web of Science ®Google Scholar
• NandikollaAG, VenugopalS, AnampaJ. Breast cancer in patients with Li-Fraumeni syndrome – a case series study and review of literature. Breast Cancer (Dove Med Press). 2017;9:207–215. doi:10.2147/BCTT.S13424128356770
   PubMed Web of Science ®Google Scholar
• BarbosaOV, ReirizAB, BoffRA, et al. Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report. Sao Paulo Med J. 2015;133:151–153. doi:10.1590/1516-3180.2012674000425271877
   PubMed Web of Science ®Google Scholar
• HenryE, VillalobosV, MillionL, et al. Chest wall leiomyosarcoma after breast conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Cancer Netw. 2012;10:939–942. doi:10.6004/jnccn.2012.0097
   Web of Science ®Google Scholar
• PetryV, Colombo BonadioR, Carneiro CagnacciAQ, et al. Radiotherapy- induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19:47–53. doi:10.1007/s10689-019-00153-531748977
   PubMed Web of Science ®Google Scholar
• StovallM, SmithSA, LangholzBM, et al. Dose to the contralateral breast from radiation therapy and risk of second primary breast cancer in the WECARE Study. Int J Radiat Oncol Biol Phys. 2008;72:1021–1030. doi:10.1016/j.ijrobp.2008.02.04018556141
   PubMed Web of Science ®Google Scholar
• BorgA, HaileRW, MaloneKE, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE Study. Hum Mutat. 2010;31(3):E1200–E1240. doi:10.1002/humu.2120220104584
   PubMed Web of Science ®Google Scholar
• Cline MS, Liao MG, Parsons MT, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752. doi:10.1371/journal.pgen.10077527
   Google Scholar
• EngelC, FischerC, ZachariaeS, et al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer. 2020;146:999–1009. doi:10.1002/ijc.3239631081934
   PubMed Web of Science ®Google Scholar
• DroogerJC, AkdenizD, PignolJP, et al. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. Breast Cancer Res Treat. 2015;154:171–180. doi:10.1007/s10549-015-3597-726467044
   PubMed Web of Science ®Google Scholar
• BernsteinJL, ThomasDC, ShoreRE, et al. Contralateral Breast Cancer after radiotherapy among BRCA 1 and BRCA 2 mutation carriers: a WECARE study report. Eur J Cancer. 2013;49(14):2979–2985. doi:10.1016/j.ejca.2013.04.02823706288
   PubMed Web of Science ®Google Scholar
• BroeksA, BraafLM, HuseinovicA, et al. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008;107:243–248. doi:10.1007/s10549-007-9543-617393301
   PubMed Web of Science ®Google Scholar
• BernsteinJL, ConcannonP; WECARE Study Collaborative Group. ATM, radiation, and the risk of second primary breast cancer. Int J Radiat Biol. 2017;93:1121–1127. doi:10.1080/09553002.2017.134436328627265
   PubMed Web of Science ®Google Scholar
• NakamuraH, YasuiY, SaitoN, et al. DNA repair defect in AT cells and their hypersensitivity to low-dose-rate radiation. Radiat Res. 2006;165:277–282. doi:10.1667/rr3519.116494515
   PubMed Web of Science ®Google Scholar
• OjimaM, BanN, KaiM. DNA double-strand breaks induced by very low X-ray doses are largely due to bystander effects. Radiat Res. 2008;170:365–371. doi:10.1667/RR1255.118763860
   PubMed Web of Science ®Google Scholar
• TeohV, TasoulisMK, GeraldG. Contralateral prophylactic mastectomy in women with unilateral breast cancer who are genetic carriers, have a strong family history or are just young at presentation. Cancers. 2020;12:140. doi:10.3390/cancers12010140
   Web of Science ®Google Scholar